Insulin aspart injection
Fiasp is a fast-acting insulin aspart injection used to control blood sugar levels in people with diabetes. Manufactured by Novo Nordisk, it's available as a subcutaneous solution in pens and cartridges, with strengths like 100 units/mL. It helps manage hyperglycemia when used with diet and exercise. This information was generated using AI and is provided for informational and research purposes only.
Find Related Datasets
Search by Tags
Click any tag below to search for similar datasets
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Fiasp is a fast-acting insulin aspart injection used to control blood sugar levels in people with diabetes. Manufactured by Novo Nordisk, it's available as a subcutaneous solution in pens and cartridges, with strengths like 100 units/mL. It helps manage hyperglycemia when used with diet and exercise. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Insulin aspart injection",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Insulin aspart injection — ANDA 208751 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208751"
}
]
|
| identifier | ANDA208751 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"drug-information",
"drug-safety",
"medications",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Insulin aspart injection |
